ClinicalTrials.Veeva

Menu

Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals (COVACHUS)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

COVID-19 Vaccines

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%. There is increasing evidence that sex-specific effects may lead to different outcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of immune response including age, gender and biological factors.

Enrollment

800 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any person, male or female, over 18 years of age who underwent vaccination and
  • anti-SARS-CoV-2 serological test after vaccination

  • having already given their consent for their biological resources to be:

    • stored in a biocollection of the Microbiology Technical Platform (PTM) having received an approval from the CPP Est-IV and declared to the Ministry of Education and Research under reference No. DC2009-1002;
    • subsequently reused, as well as the anonymized associated data, for research purposes

Exclusion criteria

  • Inability to give clear information (person in an emergency, difficulty understanding the subject, etc.)
  • Person under safeguard of justice
  • Person under guardianship or curatorship-

Trial contacts and locations

1

Loading...

Central trial contact

Saïd CHAYER, PhD, HDR; Samira FAFI-KREMER, PharmD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems